USE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPAR?) AND/OR RETINOIC ACID RECEPTOR (RXR) AGONISTS TO INHIBIT PLATELET FUNCTIONS

摘要

Methods of inhibiting mammalian platelet release of CD40 ligand, thromboxanes, or prostaglandin E2, or surface expression of CD40 ligand that involve contacting mammalian platelets with an effective amount of a PPAR? agonist, an RXR agonist, or a combination thereof. As a consequence of inhibiting CD40 ligand and thromboxane release, the present invention allows for inhibition of thrombus fon-nation by (or clotting activities of) activated platelets, as well as treating or preventing CD40 ligand-mediated conditions and/or thromboxane-mediated conditions. Use of PPAR? agonist, RXR agonist, and/or inducers of PPAR? agonist in preparing a stored blood product, and for diagnostic testing of patient samples is also disclosed.